OKYO Pharma Rings Nasdaq Opening Bell
I'm PortAI, I can summarize articles.
OKYO Pharma Ltd., a biopharmaceutical company, celebrated a milestone by ringing the Nasdaq Opening Bell, marking progress in developing treatments for neuropathic corneal pain. The event, attended by key executives, highlighted positive Phase 2 results for their lead candidate, urcosimod, and underscored their commitment to innovative ocular pain therapies. The ceremony was broadcast live on Nasdaq's channels.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments